Benefits
Digestive comfort scores in healthy adults (one trial, 400 mg alone)
In an 8-week double-blind trial in 100 healthy adults aged 30 to 50 with digestive discomfort, 60 took 400 mg Mucosave a day in capsules, once daily after dinner, and 40 took placebo. The supplement group improved on a gastrointestinal quality-of-life index and a reflux symptom scale. The published abstract does not report how the placebo group changed or how large any difference was, and this single trial has not been repeated.
Gut lining barrier in intestinal cell studies
Prickly pear cladode polysaccharides are proposed to form a protective film over the gut lining. In intestinal cell cultures, MucoSave FG kept the cell barrier tighter when the cells were exposed to the painkiller indomethacin. Neither a coating nor barrier protection has been measured in people.
Olive leaf antioxidant activity in cell studies
Olive leaf polyphenols show antioxidant activity in laboratory tests, and in intestinal cell cultures MucoSave FG lowered markers of oxidative stress and inflammatory signalling. No human study has measured an antioxidant effect, and no published study has tested the olive leaf portion of this blend separately.
Heartburn and reflux symptom scores, tested only with alginate added
In a 2-month double-blind trial in 118 adults with reflux symptoms on 2 to 6 days a week, 6 g a day of sachets each holding 400 mg MucoSave plus sodium alginate and bicarbonate cut a reflux quality-of-life score by about 74 percent versus 18 percent on placebo, and weekly heartburn and regurgitation episodes fell significantly. The paper itself cites alginate and bicarbonate as effective for reflux, so this does not isolate MucoSave.
Mechanism of action
Mucoadhesive film
Earlier cell work, summarized in a laboratory study of MucoSave FG, found that Opuntia cladode polysaccharides stick to intestinal cells, which is thought to create a physical barrier. In intestinal cell cultures the blend preserved barrier tightness and tight junction proteins against indomethacin damage. This has not been confirmed in people.
Antioxidant and anti-inflammatory signalling
Olive leaf biophenols have antioxidant activity in the laboratory, and in intestinal cell cultures MucoSave FG reduced oxidative stress, cell death markers and NF-kB inflammatory signalling. Whether this happens in the human digestive lining has not been shown.
Clinical trials
Double-blind randomized placebo-controlled trial in Italy, with participants recruited by 10 general practitioners and the product tested under medical device rules. Each sachet held 400 mg MucoSave, 500 mg sodium alginate, 300 mg sodium bicarbonate and maltodextrin (6 g/day); placebo was maltodextrin only. Two of the seven authors worked for Bionap, though no competing interests were declared. (Alecci et al. 2016, Evidence-Based Complementary and Alternative Medicine)
118 adults aged 36 to 64 with moderate reflux symptoms on 2 to 6 days a week and no diagnosed erosive esophagitis; 55 of 59 on the sachet and 53 of 59 on placebo finished the 2 months.
The GERD-HRQL score fell 74.3 percent on the sachet versus 17.8 percent on placebo, and the GSAS symptom score fell 69.8 versus 10.7 percent; the authors report these gaps (56.5 and 59.1 percentage points) as significant. Weekly heartburn and acid regurgitation episodes also fell significantly, and no adverse events were reported. Because alginate and bicarbonate ease reflux on their own, the result cannot be credited to MucoSave, and it has not been repeated.
Double-blind randomized placebo-controlled trial of 400 mg a day in capsules, taken once daily after dinner, versus placebo, allocated 60 to 40. Registered as NCT04119817 (sponsor: Messina university hospital) after the study had finished; the registration names the product Mucosave, and Bionap's 2021 white paper presents the trial as a MucoSave FG study. Funding is not stated in the abstract. (Malfa et al. 2021, Phytotherapy Research)
100 healthy adults aged 30 to 50 with gastrointestinal discomfort; the registration also required more than 1 and at most 3.5 bowel movements a week.
The abstract reports a statistically significant improvement in Gastrointestinal Quality of Life Index (GIQLI) and GERD Symptom Assessment Scale (GSAS) scores in the MucoSave group (p < .001), an effect size the authors judged clinically meaningful, and good tolerance. It does not give the size of the difference from placebo, the full text was not available to us, and no independent group has repeated the trial.